« Previous
Next »
Titles
- Initiation of voluntary recalls under 21 CFR Part 7, subpart C: guidance for industry and FDA staff1
- Institutional review board (IRB) review of individual patient expanded access submissions for investigational drugs and biological products: guidance for IRBs and clinical investigators1
- Institutional review boards: Actions needed to improve federal oversight and examine effectiveness : report to congressional requesters1
- Instructions for use: patient labeling for human prescription drug and biological products : content and format1
- Insulin affordability and the Inflation Reduction Act: Medicare beneficiary savings by state and demographics1
- Integrated efficient early care and education systems: revisiting a state-by-state analysis1
- Integrating OB/GYN and SUD care: policy challenges and opportunities1
- Integrating SUD and OB/GYN care: policy challenges and opportunities : final report1
- Integrating SUD and OB/GYN care: policy challenges and opportunities final report1
- International family planning assistance: USAID has faced implementation challenges related to U.S. policy and COVID-19 : report to congressional requesters1
- Interoperability among office-based physicians in 20191
- Interoperability and methods of exchange among hospitals in 20211
- Investigating out-of specification (OOS) test results for pharmaceutical production1
- Investigational COVID-19 convalescent plasma1
- Invisible children, invisible families: a blueprint for supporting the child care needs of American Indian and Alaska native families1
- Iowa Medicaid Fraud Control Unit: 2021 inspection1